Hoth Therapeutics Inc

Hoth Therapeutics struggles to hit Nasdaq’s $1 bid‑price rule, threatening delisting; investors watch its reverse‑split plans and pipeline moves to regain compliance.

Hoth Therapeutics Inc’s stock price has plummeted to $0.83, raising concerns about the company’s financial stability and ability to deliver on its promise of innovative therapies for atopic dermatitis.

Hoth Therapeutics Inc’s stock has experienced a rollercoaster ride on the Nasdaq, with dramatic highs and lows, raising questions about the company’s stability and ability to deliver on its promises to investors and patients.